We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $1.5B
1-Year Est. Return 518.95%
This Fund
S&P 500
This Quarter Est. Return
+16.59%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$479M
AUM Growth
+$84.4M
Cap. Flow
+$48.9M
Cap. Flow %
10.21%
Top 10 Hldgs %
91.9%
Holding
17
New
3
Increased
8
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$18.9M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$13.1M
3
MRUS
Merus
MRUS
+$5.32M
4
ABVX
Abivax
ABVX
+$3.5M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$3.34M

Top Sells

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.06M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$7.72B
$120M 24.99%
8,118,592
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$91.2M 19.04%
1,436,878
– –
EXEL icon
3
Exelixis
EXEL
$14.2B
$56.3M 11.75%
1,525,730
– –
MLYS icon
4
Mineralys Therapeutics
MLYS
$2.38B
$34.1M 7.12%
2,149,667
+1,138,512
+113% +$13.1M
EOLS icon
5
Evolus
EOLS
$410M
$32.9M 6.86%
2,731,154
+38,766
+1% +$507K
SAGE
6
DELISTED
Sage Therapeutics
SAGE
$24.3M 5.06%
3,052,538
– –
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.48B
$23.3M 4.86%
3,107,669
+111,737
+4% +$901K
ANIK icon
8
Anika Therapeutics
ANIK
$202M
$21.6M 4.5%
1,435,130
– –
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.14B
$20.5M 4.29%
701,280
+75,000
+12% +$2.49M
RVMD icon
10
Revolution Medicines
RVMD
$39.1B
$16.4M 3.43%
+465,000
New +$18.9M
MRUS
11
DELISTED
Merus
MRUS
$15.9M 3.31%
376,954
+121,954
+48% +$5.32M
YMAB
12
DELISTED
Y-mAbs Therapeutics
YMAB
$10.4M 2.17%
2,342,609
+574,627
+33% +$3.34M
ABVX
13
Abivax
ABVX
$10.8B
$7.93M 1.66%
1,269,119
+516,952
+69% +$3.5M
VRCA icon
14
Verrica Pharmaceuticals
VRCA
$92.8M
$3.98M 0.83%
899,295
+156,326
+21% +$1.01M
RZLT icon
15
Rezolute
RZLT
$474M
$410K 0.09%
+141,309
New +$615K
TYRA icon
16
Tyra Biosciences
TYRA
$1.84B
$233K 0.05%
+25,000
New +$324K
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$367M
– –
-184,826
Closed -$1.06M

Similar funds

BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return

Caligan Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Caligan Partners held 17 positions worth $479M, up 21% from $395M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Caligan Partners deployed $48.9M of net new capital in Q1 2025, opening 3 new positions and adding to 8 existing holdings. Its largest new stake was Revolution Medicines: 465,000 shares worth $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Enanta Pharmaceuticals, an estimated $1.06M sold.

  • Caligan Partners's largest Q1 2025 buy was Revolution Medicines: 465,000 shares worth $16.4M.
  • Caligan Partners added most to Mineralys Therapeutics in Q1 2025, an estimated $13.1M increase.
  • Caligan Partners fully exited Enanta Pharmaceuticals in Q1 2025, selling an estimated $1.06M.
  • Caligan Partners's ten largest holdings make up 92% of its $479M portfolio in Q1 2025.
  • Caligan Partners opened 3 new positions and closed 1 in Q1 2025.
  • Caligan Partners's portfolio value rose 21% quarter-over-quarter to $479M.

Based on Caligan Partners's 13F filing for Q1 2025, filed 15 May 2025.